Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | VCAM1 | P19320 | 8/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MERTK | Q12866 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyamine SCHEMBL6264479 | 0.95 | TDP1 (0.55) | TDP1VCAM1TSHRMAPK1RAB9A | |
| SCHEMBL8313813 | 0.87 | VCAM1 (0.56) | TDP1VCAM1TSHRMAPK1RAB9A | |
| SCHEMBL30583791 | 0.85 | TDP1 (0.60) | TDP1VCAM1TSHRMAPK1RAB9A | |
| SCHEMBL894816 | 0.85 | TDP1 (0.60) | TDP1VCAM1TSHRMAPK1RAB9A | |
| SCHEMBL28571587 | 0.82 | VCAM1 (0.51) | TDP1VCAM1TSHRMAPK1RAB9A | |
| SCHEMBL6581238 | 0.82 | VCAM1 (0.51) | TDP1VCAM1TSHRMAPK1RAB9A | |
| SCHEMBL7550938 | 0.82 | VCAM1 (0.47) | TDP1VCAM1TSHRMAPK1RAB9A | |
| SCHEMBL21961905 | 0.80 | TDP1 (0.49) | TDP1VCAM1TSHRMAPK1MERTK | |
| SCHEMBL2001345 | 0.79 | VCAM1 (0.51) | TDP1VCAM1TSHRMAPK1RAB9A | |
| SCHEMBL8390568 | 0.79 | VCAM1 (0.51) | TDP1VCAM1TSHRMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0006999-B1 | A PROCESS FOR THE PRODUCTION OF 2-CHLOROBENZONITRILE DERIVATIVES | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1981-04-01 | — | — | EP | claimed |
| US-4225534-A | FROM CHLORINATED 2-NITROBENZONITRILES | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1980-09-30 | — | — | US | claimed |
| EP-0006999-A1 | A process for the production of 2-chlorobenzonitrile derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1980-01-23 | — | — | EP | claimed |
| US-20260078135-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | ENLIVEN INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4587124-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | Enliven Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024059558-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | ENLIVEN INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| CN-102757434-B | Preparation method for industrial amplified production of anagrelide hydrochloride active pharmaceutical ingredient | HEILONGJIANG TIMEHOME PHARMACEUTICAL CO LTD | 2014-06-04 | — | — | CN | disclosed |
| CN-102757434-A | Preparation method for industrial amplified production of anagrelide hydrochloride active pharmaceutical ingredient | HEILONGJIANG TIMEHOME PHARMACEUTICAL CO LTD | 2012-10-31 | — | — | CN | disclosed |
| US-8133996-B2 | Process for the preparation of ethyl-N-(2,3-dichloro-6-nitrobenzyl)glycine hydrochloride | CIPLA LIMITED (IN) | 2012-03-13 | — | — | US | disclosed |
| US-8133996-B2 | Process for the preparation of ethyl-N-(2,3-dichloro-6-nitrobenzyl)glycine hydrochloride | CIPLA LIMITED (IN) | 2012-03-13 | — | — | US | disclosed |
| US-8133996-B2 | Process for the preparation of ethyl-N-(2,3-dichloro-6-nitrobenzyl)glycine hydrochloride | CIPLA LIMITED (IN) | 2012-03-13 | — | — | US | disclosed |
| US-5391737-A | Process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one | EGIS GYOGYSZERGYAR (HU) | 1995-02-21 | — | — | US | disclosed |
| EP-0514917-A1 | Process for and 2-(cyanoimino)-quinazoline derivatives useful as intermediates in the preparation of 6,7-di-(chloro)-1,5-di(hydro)-imidazo-[2,1-b]quinazolin-2[3H]-one and process for preparing the 2-(cyanoimino)-quinazoline derivatives | EGIS GYOGYSZERGYAR (HU) | 1992-11-25 | — | — | EP | disclosed |
| EP-0133234-B1 | IMIDAZOQUINAZOLIN-2-ONE COMPOUNDS PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | DAIICHI SEIYAKU CO., LTD. (JP) | 1989-04-12 | — | — | EP | disclosed |
| US-4610987-A | ANTICOAGULANT | DAIICHI SEIYAKU CO., LTD. (JP) | 1986-09-09 | — | — | US | disclosed |
| EP-0133234-A2 | Imidazoquinazolin-2-one compounds process for their production and pharmaceutical compositions containing said compounds | DAIICHI SEIYAKU CO., LTD. (JP) | 1985-02-20 | — | — | EP | disclosed |
| EP-0006999-B1 | A PROCESS FOR THE PRODUCTION OF 2-CHLOROBENZONITRILE DERIVATIVES | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1981-04-01 | — | — | EP | disclosed |
| US-4225534-A | FROM CHLORINATED 2-NITROBENZONITRILES | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1980-09-30 | — | — | US | disclosed |
| EP-0006999-A1 | A process for the production of 2-chlorobenzonitrile derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1980-01-23 | — | — | EP | disclosed |
| US-4146718-A | BLOOD PLATELET ANTIAGGREGATIVE AGENT | BRISTOL-MYERS COMPANY (US) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078135-A1 | POLYCYCLIC QUINAZOLINES FOR INHIBITION OF ERBB2 | ERBB2, BRCA1, ERBB3 | TDP1 2757/4885VCAM1 3940/4885TSHR 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.